[Prolonged effect against exercise-induced bronchospasm: salmeterol versus sodium cromoglycate]

Area of Science:

• Pulmonology
• Pharmacology
• Exercise Physiology

Background:

• Exercise-induced asthma (EIA) is a common condition affecting respiratory function during physical activity.
• Current treatments aim to prevent bronchoconstriction triggered by exercise.
• Salmeterol and sodium cromoglycate are established medications for asthma management.

Purpose of the Study:

• To compare the efficacy and duration of action of salmeterol versus sodium cromoglycate in subjects with isolated EIA.
• To evaluate the effectiveness of these medications in preventing exercise-induced bronchoconstriction.

Main Methods:

• A multicenter, double-blind, double-placebo, cross-over trial was conducted.
• Nineteen subjects with EIA received either salmeterol (100 mcg) or sodium cromoglycate (40 mg) before exercise.
• Pulmonary function tests (FEV1, FEF25-75%) were assessed at baseline and at 30 minutes and 7 hours post-inhalation.

Main Results:

• Salmeterol significantly improved FEV1 and FEF25-75% at 30 minutes post-inhalation compared to baseline.
• Salmeterol showed superiority over sodium cromoglycate across all measured parameters at 7 hours post-inhalation.
• Both medications were well-tolerated by the study participants.

Conclusions:

• Salmeterol offers a longer duration of effect and superior efficacy compared to sodium cromoglycate for EIA management.
• Salmeterol represents a valuable therapeutic option for individuals suffering from exercise-induced asthma.
• The findings support the use of salmeterol for sustained relief from exercise-induced bronchoconstriction.